DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for fallopian tube disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFallopian tube disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fallopian tube disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KN motif and ankyrin repeat domains 1 (KANK1) — KANK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5YBU · 1.89 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2015 case report describes a fallopian tube papilloma found incidentally in a 45-year-old woman operated for uterine prolapse. The right tube was dilated at the infundibular region and contained friable grey-white tissue. Microscopy showed delicate branching papillae lined by a single layer of epithelium resembling normal tubal lining. No features of reactive hyperplasia or aggressive behaviour were present. This is a single case, not a trial, and provides no data on treatment or outcomes beyond the pathological description.
A 2009 quality assessment of Chinese studies on interventional recanalisation of fallopian tubes reviewed 157 therapeutic articles and identified 30 controlled trials (25 randomised, 5 non-randomised). Only 30% of these trials met accurate criteria for case selection and exclusion, 40% met accurate criteria for effect determination, and 13.3% used a definite method of randomisation. One article (3.3%) used a single-blinded method. Jadad scores were low: 2 trials scored 0 points, 15 scored 1 point, and 8 scored 2 points. The authors concluded that the quality of studies on interventional recanalisation is poor and does not meet evidence-based medicine standards.
A 2020 article discusses the classification of fluid accumulation in the fallopian tube, referencing 1890 lectures by Professor K.F. Slavyanskiy that grouped hydrosalpinx, pyosalpinx, haematosalpinx, and tubo-ovarian cysts under retention cysts. No original data, patient numbers, or treatment outcomes are provided. This is a historical review, not a clinical study.
Across these abstracts, no drug is mentioned, no treatment efficacy is reported, and no survival or response rates are given. What is missing is any controlled clinical trial of a drug for fallopian tube disease, any prospective randomised data on interventions, and any patient stratification by disease subtype or aetiology.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Kathmandu University Medical Journal · 2015 · 3 citations · open access
Fallopian Tube Papilloma – Case Report of a Rare Tumor
AbstractFallopian tube neoplasms are rare. We report a rare case of fallopian tube papilloma discovered incidentally in a 45 year old female, operated for procidentia. Right tube was dilated at the infundibular region, with friable grey white tissue in the lumen. Microscopy showed delicate branching papillae lined by a single layer of epithelium resembling tubal lining. There were no features to suggest a reactive hyperplasia in response to inflammation or of aggressive behaviour.
Quality assessment of studies on interventional recanalization of fallopian tube in China
AbstractObiective To evaluate the current status of studies on interventional recallalization of fallopian tube.Methods According to the standard of evidence-based medicine,literatures were analyzed by two readers in three time periods:1997 to 2000,2001 to 2004 and 2005 t0 2008.Two separate evaluation results were tested by the statistical method Kappa to test its consistency.Scores of clinical controlled trials (CCT)and randomized controlled trials(RCT)were calculated according to Jadad score scale.The accurate criteria of case selection,case exclusion,and effect determination;the method of randomization;the number of samples:the comparability of baseline;the blinded procedure;the therapeutic method;the method of statistical analysis:the follow-up cases; the drop-out cases and the conclusions derivation of RCT and CCT into descriptive analysis were evaluated Results One hundred and fifty seven therapeutic articles were searched and 30 RCT and CCT articles(25 RCT and 5 CCT)were analyzed.The Kappa value was 0.85 and P＜0.05 indicating that the evaluation was in good consistency.2,15 and 8 RCT received 0 point,1 point and 2 points respectively in Jadad score scale.RCT and CCT contained 9 articles(30.0%)fulfilled the accurate criteria of case selection and exclusion:12 articles(40.0%)met the accurate criteria of effect determination:4 articles(13.3%)utilized the definite method of randomization;27 articles (90.0%)had the number of sample beyond 60;14 articles(46.7%)met the baseline comparability;only 1 article(3.3%)used the single-blinded method,17 articles(56.7%)utilized the method of statistical analysis;13(43.3%)mentioned follow-up in articles;4(13.3%)mentioned drop-out cases in the articles and 14(46.7%)articles had the conclusions derived by considering the statistical significance and clinical significance.Conclusion The quality of studies on interventional recanalization of fallopian tube is poor and could not meet the standard of evidence-based medicine.
Key words:
Fallopian tube obstruction; Radiology,international; Bibliometrics
Journal of obstetrics and women s diseases · 2020 · 0 citations · open access
ACCORDING TO THE ACCUMULATION OF LIQUID IN THE UTERINE TUBE. SEVERAL ANIMAL EXPERIENCES
AbstractDiseases of the fallopian tubes occupy a prominent place in modern gynecology, and among these diseases, serious attention is paid clinically to the accumulation of fluid in the tube cavity. Professor K.F. Slavyanskiy in his lectures, read in November 1890 at the clinic of the Imperial Military Medical Academy, which he headed, examined in detail the issue of retention cysts of the fallopian tubes and under this name grouped diseases known as hydrosalpinx, pyosalpinx, haematosalpinx, cystes tubo-ovariales.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
